Is CLNN or MDCX more profitable?

Medicus Pharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Medicus Pharma N/A -16,319.59% -263.24%

Does the media favor CLNN or MDCX?

In the previous week, Clene had 2 more articles in the media than Medicus Pharma. MarketBeat recorded 8 mentions for Clene and 6 mentions for Medicus Pharma. Clene's average media sentiment score of 0.53 beat Medicus Pharma's score of 0.18 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, CING or MDCX?

Cingulate is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$4.23 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is CING or MDCX more profitable?

Cingulate's return on equity of -347.67% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -347.67% -153.02% Medicus Pharma N/A -16,319.59% -263.24%

Does the media prefer CING or MDCX?

In the previous week, Cingulate had 1 more articles in the media than Medicus Pharma. MarketBeat recorded 7 mentions for Cingulate and 6 mentions for Medicus Pharma. Cingulate's average media sentiment score of 1.16 beat Medicus Pharma's score of 0.18 indicating that Cingulate is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MDCX or MNOV more profitable?

Medicus Pharma has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -25.81% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -16,319.59% -263.24% MediciNova -1,168.70% -25.81% -23.74%

Does the media refer more to MDCX or MNOV?

In the previous week, Medicus Pharma had 3 more articles in the media than MediciNova. MarketBeat recorded 6 mentions for Medicus Pharma and 3 mentions for MediciNova. MediciNova's average media sentiment score of 0.75 beat Medicus Pharma's score of 0.18 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SCLX or MDCX?

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 3,113.14%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is SCLX or MDCX more profitable?

Medicus Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% Medicus Pharma N/A -16,319.59% -263.24%

Does the media prefer SCLX or MDCX?

In the previous week, Medicus Pharma had 3 more articles in the media than Scilex. MarketBeat recorded 6 mentions for Medicus Pharma and 3 mentions for Scilex. Scilex's average media sentiment score of 1.50 beat Medicus Pharma's score of 0.18 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, DWTX or MDCX?

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is DWTX or MDCX more profitable?

Dogwood Therapeutics' return on equity of -88.30% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -88.30% -38.98% Medicus Pharma N/A -16,319.59% -263.24%

Does the media prefer DWTX or MDCX?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 6 articles in the media. Medicus Pharma's average media sentiment score of 0.18 beat Dogwood Therapeutics' score of -0.07 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Medicus Pharma (MDCX) Competitors

$0.28 -0.07 (-20.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.28 0.00 (-0.04%)

As of 07:59 PM Eastern

Compare

MDCX vs. CLNN, CING, MNOV, SCLX, and DWTX

Should you buy Medicus Pharma stock or one of its competitors? Medicus Pharma's main competitors and comparable companies include Clene (CLNN), Cingulate (CING), MediciNova (MNOV), Scilex (SCLX), and Dogwood Therapeutics (DWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Medicus Pharma compare to Clene?

Clene (NASDAQ:CLNN) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Clene currently has a consensus target price of $33.25, indicating a potential upside of 703.14%. Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 3,113.14%. Given Medicus Pharma's higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Clene has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

In the previous week, Clene had 2 more articles in the media than Medicus Pharma. MarketBeat recorded 8 mentions for Clene and 6 mentions for Medicus Pharma. Clene's average media sentiment score of 0.53 beat Medicus Pharma's score of 0.18 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Clene has higher revenue and earnings than Medicus Pharma. Clene is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	264.55	-$26.17M	-$3.20	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Medicus Pharma	N/A	-16,319.59%	-263.24%

23.3% of Clene shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Clene beats Medicus Pharma on 11 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Cingulate?

Cingulate (NASDAQ:CING) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Cingulate is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Cingulate's return on equity of -347.67% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-347.67%	-153.02%
Medicus Pharma	N/A	-16,319.59%	-263.24%

Cingulate currently has a consensus target price of $27.33, indicating a potential upside of 437.00%. Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 3,113.14%. Given Medicus Pharma's higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

41.3% of Cingulate shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cingulate has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market.

In the previous week, Cingulate had 1 more articles in the media than Medicus Pharma. MarketBeat recorded 7 mentions for Cingulate and 6 mentions for Medicus Pharma. Cingulate's average media sentiment score of 1.16 beat Medicus Pharma's score of 0.18 indicating that Cingulate is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cingulate beats Medicus Pharma on 7 of the 12 factors compared between the two stocks.

How does Medicus Pharma compare to MediciNova?

Medicus Pharma (NASDAQ:MDCX) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

9.9% of MediciNova shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Medicus Pharma had 3 more articles in the media than MediciNova. MarketBeat recorded 6 mentions for Medicus Pharma and 3 mentions for MediciNova. MediciNova's average media sentiment score of 0.75 beat Medicus Pharma's score of 0.18 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Medicus Pharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Medicus Pharma presently has a consensus target price of $9.00, indicating a potential upside of 3,113.14%. MediciNova has a consensus target price of $8.33, indicating a potential upside of 536.13%. Given Medicus Pharma's higher possible upside, research analysts clearly believe Medicus Pharma is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Medicus Pharma has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -25.81% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-16,319.59%	-263.24%
MediciNova	-1,168.70%	-25.81%	-23.74%

MediciNova has higher revenue and earnings than Medicus Pharma. MediciNova is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
MediciNova	$410K	157.26	-$12M	-$0.23	N/A

Summary

MediciNova beats Medicus Pharma on 11 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Scilex?

Scilex (NASDAQ:SCLX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Medicus Pharma has lower revenue, but higher earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.90	-$358.73M	-$40.47	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 3,113.14%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Medicus Pharma had 3 more articles in the media than Scilex. MarketBeat recorded 6 mentions for Medicus Pharma and 3 mentions for Scilex. Scilex's average media sentiment score of 1.50 beat Medicus Pharma's score of 0.18 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scilex has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

Medicus Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Medicus Pharma	N/A	-16,319.59%	-263.24%

69.7% of Scilex shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Medicus Pharma beats Scilex on 9 of the 15 factors compared between the two stocks.

How does Medicus Pharma compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 6 articles in the media. Medicus Pharma's average media sentiment score of 0.18 beat Dogwood Therapeutics' score of -0.07 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 458.14%. Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 3,113.14%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Dogwood Therapeutics' return on equity of -88.30% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-88.30%	-38.98%
Medicus Pharma	N/A	-16,319.59%	-263.24%

9.1% of Dogwood Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dogwood Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Summary

Medicus Pharma beats Dogwood Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.37M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.11	775.15	269.06	25.28
Price / Sales	N/A	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	-9.34	11.60	12.91	6.24
Net Income	-$35.46M	$2.77B	$3.45B	$347.60M
7 Day Performance	-6.51%	0.17%	1.12%	1.07%
1 Month Performance	-23.01%	0.35%	1.79%	1.03%
1 Year Performance	-85.85%	161.52%	67.69%	20.77%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	2.235 of 5 stars	$0.28 -20.9%	$9.00 +3,113.1%	-83.1%	$22.37M	N/A	N/A	N/A	Earnings Report
CLNN Clene	1.9174 of 5 stars	$5.34 -0.7%	$33.25 +522.7%	+14.8%	$68.24M	$134K	N/A	100	News Coverage Earnings Report Gap Up
CING Cingulate	2.9748 of 5 stars	$5.05 +2.2%	$27.33 +441.3%	+35.6%	$68.02M	N/A	N/A	20	News Coverage Positive News Earnings Report
MNOV MediciNova	1.8638 of 5 stars	$1.36 +2.3%	$8.33 +512.7%	+3.1%	$66.94M	$410K	N/A	10	News Coverage Earnings Report Analyst Downgrade
SCLX Scilex	1.7639 of 5 stars	$6.94 +6.4%	N/A	-67.9%	$58.92M	$30.25M	N/A	80	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. CLNN, CING, MNOV, SCLX, and DWTX

How does Medicus Pharma compare to Clene?

Summary

How does Medicus Pharma compare to Cingulate?

Summary

How does Medicus Pharma compare to MediciNova?

Summary

How does Medicus Pharma compare to Scilex?

Summary

How does Medicus Pharma compare to Dogwood Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. CLNN, CING, MNOV, SCLX, and DWTX

How does Medicus Pharma compare to Clene?

Do analysts prefer CLNN or MDCX?

Which has more volatility & risk, CLNN or MDCX?

Does the media favor CLNN or MDCX?

Which has preferable valuation and earnings, CLNN or MDCX?

Is CLNN or MDCX more profitable?

Do institutionals & insiders have more ownership in CLNN or MDCX?

Summary

How does Medicus Pharma compare to Cingulate?

Which has better earnings and valuation, CING or MDCX?

Is CING or MDCX more profitable?

Do analysts prefer CING or MDCX?

Do insiders & institutionals believe in CING or MDCX?

Which has more volatility & risk, CING or MDCX?

Does the media prefer CING or MDCX?

Summary

How does Medicus Pharma compare to MediciNova?

Do insiders and institutionals have more ownership in MDCX or MNOV?

Does the media refer more to MDCX or MNOV?

Which has more volatility & risk, MDCX or MNOV?

Do analysts rate MDCX or MNOV?

Is MDCX or MNOV more profitable?

Which has stronger valuation & earnings, MDCX or MNOV?

Summary

How does Medicus Pharma compare to Scilex?

Which has higher earnings & valuation, SCLX or MDCX?

Do analysts prefer SCLX or MDCX?

Does the media prefer SCLX or MDCX?

Which has more risk & volatility, SCLX or MDCX?

Is SCLX or MDCX more profitable?

Do institutionals & insiders have more ownership in SCLX or MDCX?

Summary

How does Medicus Pharma compare to Dogwood Therapeutics?

Does the media prefer DWTX or MDCX?

Do analysts prefer DWTX or MDCX?

Is DWTX or MDCX more profitable?

Do institutionals and insiders have more ownership in DWTX or MDCX?

Which has more risk and volatility, DWTX or MDCX?

Which has preferable earnings and valuation, DWTX or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools